1.1
Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group.
Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).
Clin Res Hepatol Gastroenterol 2012;36(3): 214-221.
1.2
Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B; and the HEPAVIH Study Group.
Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13).
J Hepatol 2012;56(3): 745-747.
1.3
Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; the ANRS CO 13 HEPAVIH Study Group.
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Antivir Ther. 2012 Oct 10. doi: 10.3851/IMP2419. [Epub ahead of print].
1.4
Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group.
Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).
BMC Health Serv Res. 2012;12:12:59.
1.5
Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P.
Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.
J Hepatol 2012;56(4): 862-868.
1.6
Trimoulet P, Merchadou L, Winnock M, Loko MA, Fleury H, Salmon D, Dabis F, Neau D; ANRS CO 13 HEPAVIH Study Group.
Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?
J Virol Methods 2012;181(1): 131-133.
1.7
COHERE, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe, EuroCoord
Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro J, Furrer H, Castagna A, Wit Sd, Munoz J, Kjaer J, Colin C, Grarup J, Chêne G, Bucher H.
CD4 Cell Count and the Risk of AIDS or Death in HIVInfected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE.
PLoS Med 2012;9(3):e1001194.
1.8
COHERE in EuroCoord,
Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G.
All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
Int J Epidemiol 2012;41(2):433-445.
1.9
Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD.
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
HIV Med 2012;13 (1):62-72.
1.10
De Wolf F, Sabin C, Kirk O, Thorne C, Chêne G, Porter K.
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience.
Clin Invest 2012;2(3):255-264.
1.11
HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
Effect of hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients.
Antivir Ther 2012 [E-pub ahead of print]
1.12
Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, de Olalla PG, Porter K, del Amo J, Cascade Collaboration in EuroCoord.
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia.
Clin Infect Dis 2012;54(1):111-118
1.13
Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R.
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
Clin Infect Dis. 2012 Oct 22. [Epub ahead of print]
1.14
Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O.
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
AIDS 2012;26 (3):315-323.
1.15
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; the Collaborating Cohorts and Study Groups.
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
Int J Epidemiol. 2012 Nov 12. [Epub ahead of print]
1.16
Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD.
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
Antivir Ther 2012 [Epub ahead of print]
1.17
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J.
The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
HIV Med 2012;13(2):89-97.
1.18
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE.
PLoS Med. 2012; 9: e1001194.
1.19
Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G, CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
PLoS One 2012;7(3):e32369.
1.20
Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord.
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
AIDS 2012;26(15):1917-1926.
1.21
Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, d'Arminio Monforte A, Friis-Møller N, Lundgren JD, Law MG on behalf of the D:A:D Study Group.
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
Journal of the International AIDS Society 2012;15:17426.
1.22
Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O.
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study.
BMC Infect Dis 2012;12(1):229.
1.23
Pursuing Later Treatment Option II (PLATO II) project team, Observational HIV Epidemiological Research Europe (COHERE) Group,
Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheue rG, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A.
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
Lancet Infect Dis 2012;12(2):119-127.
1.24
Pursuing Later Treatment Options II (PLATO II) project team, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group,
Nakagawa F, Lodwick R, Costagliola D, Sighem Av, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, Wit SD, Stephan C, Obel N, Fätkenheuer G, Castagna A, Touloumi G, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A.
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
J Acquir Immune Defic Syndr 2012;59(3):294-299.
1.25
Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A ; EuroSIDA in EuroCoord.
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.
PLoS One 2012;7(7):e41673.
1.26
Worm S, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, Montforte, AD, Law M, Philipps A, Ryom L, Dabis F, Weber R, Sabin C, D:A:D Study Group.
Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke.
J Infect Dis 2012;205(4):535-539.
1.27
Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K, CASCADE Collaboration in EuroCoord.
Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.
Antivir Ther 2012;17(6):1039-1048.
2.1
Dauchy F, Lawson-Ayayi S, de La Faille R, Morlat P, Wirth G, Miremont-Salamé G, Geffard S, Dabis F, Dupon M for the Groupe d'Epidémiologie du SIDA en Aquitaine.
Abnormal tubular function and chronic kidney disease in HIV-infected patients, ANRS CO3 Aquitaine Cohort.
22nd European Congress of Clinical Microbiology and Infectious Diseases, London - United Kingdom, 31 March – 3 April 2012.
2.2
Dauchy F-A, Lawson-Ayayi S, De La Faille R, Morlat P, Rigothier C, Wirth G, Miremont-Salamé G, Blaizeau M.J, Dabis F, Dupon M.
Insuffisance rénale chronique et marqueurs urinaires chez les personnes infectées par le VIH, Cohorte ANRS CO3 Aquitaine.
6e Conférence Francophone VIH/SIDA Genève (Suisse) du 25 au 28 mars 2012 [Abstract 286/52S].
2.3
Dufouil C, Richert L, Bruyand M, Amieva H, Dauchy F-A , Greib C, Dartigues J-F Dartigues, Neau D, Dabis F, Morlat P, Bonnet F, Chêne and the ANRS C03 Aquitaine Study Group
Type 2 diabetes is associated with lower cognitive performances in a cohort of HIV-infected patients.
ANRS C03 Aquitaine Cohort, Bordeaux, France, 2007-2009.
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [Abstract 75].
2.4
Dufouil C, Richert L, Bruyand M, Amieva H, Dauchy F.-A, Dartigues J-F, Neau D, Dabis F, Morlat P, Bonnet F, Chêne G, ANRS CO3 Aquitaine Study Group.
Type 2 diabetes is associated with lower cognitive performances in a cohort of HIV-positive patients. ANRS CO3 Aquitaine Cohort, Bordeaux, France, 2007-2009.
19th International AIDS Conference, 22-27 July 2012, Washington DC, US [Oral Abstract THAB0203].
2.5
Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Pellegrin J-L, Moreau J-F, Thiebaut R, Pellegrin I, and the ANRS CO3 Aquitaine Cohort.
Impact of Immune Response to CMV on Chronic Immune Activation in HIV-infected Patients on Successful cART: The ACTHIV Study .
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Poster Abstracts 272].
2.6
Bruyand M, Lejeune M, Reigadas S, Vandenhende MA, Joly P, Dauchy FA, Greib C, Geffard S, Decoin M, Morlat P, and Dabis F, for the Groupe d’Epidémiologie Clinique du Sida en Aquitaine.
Characterization of loss to follow-up patterns in the ANRS CO3 Aquitaine Cohort, 2000-2008.
16th International Workshop on HIV Observational Databases, 29-31 March 2012. Athens (Greece) [Abstract 108].
2.7
Carrieri M.P, Cohen J, Salmon D, Dabis F, Spire B, Winnock M.
Impact de la consommation de café sur les effets indésirables pendant le traitement du VHC chez des patients co-infectés par le VIH et le VHC (ANRS CO13 HEPAVIH) : une hypothèse de recherche possible.
6e Conférence Francophone VIH/SIDA Genève (Suisse) du 25 au 28 mars 2012 [Abstract 03/37S]
2.8
Pambrun E, Winnock M, Loko MA, Sogni P, Sadr FB, Dabis F, and Salmon D, on behalf of the HEPAVIH –ANRS CO13 study group.
Mortality risk and causes of death in a cohort of HIV/HCV infected patients in France : ARNSC013 HEPAVIH.
16th International Workshop on HIV Observational Databases, 29-31 March 2012,Athens (Greece) [Abstract 37].
2.9
Abgral S, Ingle S, Saag M, Cavassini M, Hogg R, Crane H, May M, Sterne J, and the Antiretroviral Therapy Cohort Collaboration (ART-CC).
Cumulative Incidence of and Risk Factors for Changes to First ART Regimen and Death Prior to a Change: The Antiretroviral Therapy Cohort Collaboration.
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US [Poster Abstracts 637].
2.10
BakoyannisG, Touloumi G, on behalf of CASCADE Collaboration inEuroCoord.
Late entry bias in cohort studies with competing endpoints.
33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen (Norway), [Abstract C 26.4]
2.11
Cozzi-Lepri A, Kjaer J, Perdersen C, Paredes R, D’Arminio Monforte A, Reiss P, Ristola M, Phillips and Lundgren J.
Predicting the extent of drug resistance using previous history of virological failure : Classical and Bayesian approaches.
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [Abstract 62].
2.12
Cozzi-Lepri A, Phillips AN, Jablonowska E, Colebunders R, Pedersen C, Hemmer R, Ledergerber B, Lundgren J.
Estimation of percentage of HIV-infected people with limited antiretroviral drug options in a closed observational setting over the period 2006-2010 and beyond.
16th International Workshop on HIV Observational Databases, 29-31 March 2012. Athens (Greece) [Abstract 111].
2.13
D’Arminio Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm S, Phillips A, Lundgren J, and Sabin C.
ATV-containing ART Is Not Associated with an Increased Risk of Cardio- or Cerebro-vascular Events in the D:A:D Study.
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US [Poster Abstracts 823].
2.14
Grint D, Mocroft A, Vogel M, Beniowski, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O and Peters for EroSIDA in Eurocord.
Temporal changes and regional diffeences in treatment umtake of hepatitis C therapy in EuroSIDA.
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [ORAL Abstract 2].
2.15
Ingle S, J Gill, Mugavero M, Lewden C, Abgrall S, Fätkenheur G, Reiss P, May M, Sterne JAC and Saag for the Antiretroviral Therapy Cohort Collaboration (ART-CC)
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [Abstract 74].
2.16
Ingle S, Gill J, Mugavero M, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, May M, Sterne J, Saag M, and The Antiretroviral Therapy Cohort Collaboration (ART-CC).
Distribution of Age at Death and Effects of Immunosuppression and ART Duration Vary according to Cause of Death in HIV-1+ People.
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US [Poster Abstracts 640].
2.17
Kamara DA, Worm SW, Sabin CA, Smith CJ, Philips and Lundgren for the D:A: D Study Group.
Fasting and non-fasting cholesterol and risk of myocardial (MI) : The D:A:D study.
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [Abstract 70].
2.18
Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Porter K for CASCADE Collaboration in EuroCoord.
Identification of severe primary HIV infection through clinical, immunological and virological definitions.
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Poster Abstracts 550].
2.19
Lundgren J on behalf of the COHERE Late Presenters working group.
Characteristics of individuals presenting late for care across Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).
19th International AIDS Conference, 22-27 July 2012, Washington DC, US [Oral Abstract THAB0303].
2.20
May M, Birnie K, Justice A, Hogg B, Ingle S, Sterne JAC on behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC).
History of injection drug use (IDU) and hepatitis C as risk factors for mortality in the ART-CC.
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [Abstract 35].
2.21
Olson A, Meyer L, Prins M, Thiébaut R, Guiguet M, Chaix M-L, Amornkul P, Babiker A and Porter K for CASCADE Collaboration in EuroCoord.
Proportion of HIV elite controllers and loss of elite status according to two commonly used definitions.
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Poster Abstracts 290].
2.22
Pantazis N, Kenward M, Touloumi G on behalf of CASCADE Collaboration in EuroCoord.
Performance of parametric survival models under non-random interval censoring: a simulation study.
33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen (Norway) [Abstract P 22.26].
2.23
Reekie J, on behalf of the late presenters working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
Temporal trends in late presenters across the European continent.
16th International Workshop on HIV Observational Databases, 29-31 March 2012, Athens (Greece) [Abstract 91].
2.24
Signe Worm on behalf of the D:A:D Study Group.
NADM and Immunosuppression: The D:A:D Study.
19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US [Oral Abstracts 130].
2.25
Smith R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Malyuta R, Porter K on behalf of CASCADE Collaboration in EuroCoord.
High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults.
19th International AIDS Conference, 22-27 July 2012, Washington DC, US [Abstract no. TUPE191].
2.26
Van der Helm J, Geskus, Sabin, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M on behalf of the CASCADE collaboration.
Effect of hepatitis C coinfection on cause-specific mortality following HIV seroconversion in the pre-cART and cART eras.
47th annual meeting of the European Association for the Study of Liver (EASL), 18-22 April 201,Barcelona, Spain. Journal of Hepatology 2012 vol 56 S1-S20,[Oral Abstract 18].
3.1
Collin A.
Infections bactériennes et fongiques au sein de la Cohorte ANRS C03 Aquitaine de personnes vivant avec le VIH : Critères de validation et descriptif.
Thèse de Médecine n° 99 de l’Université Bordeaux Segalen 2012.
3.2
Bandré C.
Facteurs associés à la survenue d’une première infection bactérienne chez les patients vivants avec le VIH-1 : La Cohorte ANRS CO3 Aquitaine, 2000-2011.
Mémoire de Master 2 Sciences Technologies, Santé : Mention Santé Publique Option Epidémiologie clinique. Bordeaux: Université Segalen 2012.
3.3
Rwagitinywa J.
Arrêts, causes d’arrêt et facteurs associés à arrêt des antirétroviraux chez les patients VIH positifs, Cohorte ANRS C03 Aquitaine 2005-2010.
Mémoire de Master Professionnel Pharmaco-Epidémiologie-Pharmacovigilance, Université Bordeaux Segalen 2012.
4.1
Dr Dominique Costagliola (Inserm U 943) :
[>>> Des cohortes VIH à l’épidémie cachée en France]
4.2
4.3
Dr Pantxica Bellecave (UMR 5234CNRS) :
[>>> Quand le virus fait de la résistance]
4.4
Pr Jonathan Sterne (Université de Bristol) :
[>>> When to start and guidelines : how do cohorts contribute ?]
4.5
Pr Philippe Morlat (CHU & Université de Bordeaux) :
[>>> 25 ans d’antirétroviraux]
4.6
Pr Fabrice Bonnet (CHU & Université de Bordeaux) :
[>>> La morbidité VIH au début du 21ème siècle]